Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biotech sector faces innovation capital bottleneck

This article was originally published in Scrip

Executive Summary

While at first glance it appears that biotech financing is holding up, closer scrutiny of the numbers by Ernst & Young confirms what most biotech executives have been thinking – the funds for backing new innovation are drying up. In its latest annual Beyond Borders survey of the industry, Ernst & Young, the global financial and business advisory firm, warns that the biotech sector will need to adopt new behaviours if it is continue to innovate sustainably.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts